MedTrace Logo

40Hz tACS in Treating Cognitive Function and Modulating Neurophysiology of Patients With Alzheimer's Disease

NCT05723172 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-11-13

No results posted yet for this study

Summary

Gamma brain activity is crucial for cognitive function and intra-brain communication. Gamma frequency stimulation via transcranial alternating current stimulation(tACS) might alleviate memory deficits on both animal models of Alzheimer's disease (AD) and clinical trial. The study aims to assess the safety and efficacy of tACS on cognitive function and modulating neurophysiology in patients with AD.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

active tACS

40 mins tACS for 10 consecutive daily sessions

DEVICE

sham tACS

40 mins sham tACS for 10 consecutive daily sessions

Sponsors & Collaborators

  • Che-Sheng Chu

    lead OTHER

Principal Investigators

  • Che-Sheng Chu, MD · Department of Psychiatry, Kaohsiung Veterans General Hospital, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05723172 on ClinicalTrials.gov